21617-19-6

Usage

Uses

Used in Veterinary Medicine:
3-[(4-chlorophenyl)amino]propanoic acid is used as an anti-inflammatory agent for the treatment of pain and inflammation in dogs and cats. It is particularly effective in managing arthritis and other musculoskeletal conditions, providing relief and improving the quality of life for these animals.
Used in Pain Management for Pets:
Carprofen serves as an analgesic, helping to control pain in pets, which is crucial for their comfort and well-being. Its use is typically prescribed by veterinarians who may recommend it for post-operative pain or for conditions that cause chronic discomfort.
Used in Caution for Animals with Specific Health Conditions:
While generally well-tolerated, 3-[(4-chlorophenyl)amino]propanoic acid is used with caution in animals that have pre-existing kidney or liver disease, or a history of gastrointestinal ulcers, due to potential side effects and the need to monitor for adverse reactions in these populations.

Upstream product

• 57-57-8 β-Propiolactone 
• 106-47-8 4-chloro-aniline 
• 41833-57-2 3-(4-chlorophenylamino)propanenitrile 
• 76227-93-5 ethyl 3-((4-chlorophenyl)amino)propanoate 
• 79-10-7 acrylic acid 

Downstream Products

• 106-47-8 4-chloro-aniline 
• 79-10-7 acrylic acid 

Relevant academic research and scientific papers

Method for preparing 1-(4-chlorphenyl)-pyrazolidine-3-one

The invention relates to the field of bactericide synthesis, and discloses a method for preparing 1-(4-chlorphenyl)-pyrazolidine-3-one. The method comprises the following steps: 1) reacting parachloroaniline with acrylic acid to obtain an addition reactio

2,3-dihydro-1H-quinoline-4-ketone thiosemicarbazone derivatives as well as preparation method and application thereof

The invention discloses 2,3-dihydro-1H-quinoline-4-ketone thiosemicarbazone derivatives as well as a preparation method and application thereof. The structural formula of the derivatives is as shown in a formula (I): (the formula is as shown in the description), wherein R1 is halogen, alkyl or alkoxy; R2 is hydrogen, halogen or alkoxy; R3 is hydrogen or halogen; R4 is hydrogen or halogen; X is hydrogen, acetyl or nitryl; and Y is hydrogen or phenyl. The derivatives can obviously inhibit proliferation of tumor cells, and has significant inhibition effect on multiple cancer cell strains such asbreast cancer cells, melanoma cells and prostatic cancer cells; and the anti-tumor activity is obviously better than that of a broad-spectrum anti-cancer medicine cis-platinum. In addition, the preparation process of the derivatives is simple, the conditions are mild, the sources of the raw materials are rich, the production cost is low, and potential medicinal value and good application prospectin the aspect of preparing a novel anti-tumor medicine are achieved.

Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase

The invention provides compounds of formula I: or pharmaceutically salts thereof where R1, R2, and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula I, methods of preparing the desired compounds, and methods of treating cognitive disorders, such as Alzheimer's disease, using the compounds or salts of formula I.

Kinetics and mechanism of thermal gas-phase elimination of α- and β- (N-arylamino)propanoic acid: Experimental and theoretical analysis

2-(N-Phenylamino)propanoic acid 1a and 3-(N-phenylamino)-propanoic acid 2a together with four of their aryl analogues were pyrolysed in the gas-phase. The reactions were homogeneous and free from catalytic and radical pathways. Analysis of the pyrolysate of 1 showed the elimination products to be carbon monoxide, acetaldehyde and aniline, while the pyrolysate of 2 reveals the formation of acrylic acid in addition to aniline. Theoretical study of the pyrolysis of 2 using an ab initio SCF method lend support to a reaction pathway involving a 4-membered cyclic transition state.

Pyridocarbazole derivatives having cGMP-PDE inhibitory activity

PCT No. PCT/JP97/01829 Sec. 371 Date Jan. 29, 1998 Sec. 102(e) Date Jan. 29, 1998 PCT Filed May 29, 1997 PCT Pub. No. WO97/45427 PCT Pub. Date Dec. 4, 1997The invention relates to novel pyridocarbazole derivatives having highly selective action in inhibiting cyclic GMP-phosphodiesterase (hereinafter abbreviated as cGMP-PDE), processes for producing such derivatives, agents containing at least one of such derivatives as an active ingredient for preventing and/or treating pulmonary hypertension, ischemic heart diseases or diseases against which the cGMP-PDE inhibitory action is effective, and intermediates useful for the production of pyridocarbazole derivatives.